Dr. Lal Path Labs Ltd. has informed the Exchange about Copy of Newspaper Publication
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Lal PathLabs has submitted to NSE and BSE copies of newspaper advertisements (published in Financial Express and Jansatta on August 1, 2025) containing its financial results for the quarter ended June 30, 2025, as required under SEBI Regulation 30 and 47. On a consolidated basis, total income from operations rose to ₹6,979 million from ₹6,225 million in Q1 FY25, a growth of about 12%. Net profit after tax increased to ₹1,340 million from ₹1,078 million, up roughly 24% year-on-year. Basic EPS stood at ₹15.88 compared to ₹12.79 in the same quarter last year. The standalone business also showed healthy growth, with total income of ₹6,670 million and profit after tax of ₹1,293 million. The results were reviewed by the Audit Committee and approved by the Board on July 31, 2025.
This is a routine regulatory disclosure — the actual Q1 numbers were already announced earlier. It confirms solid double-digit revenue and profit growth for the diagnostics major, but is unlikely to move the stock since no new information is being shared. The filing simply fulfils the newspaper publication requirement under SEBI rules.